Sai Parenterals Share Price Target 2026, 2027, 2030, 2040, 2050
Sai Parenterals is a medicine company that makes different types of medicines, especially injections like vials and ampoules, along with tablets, capsules, liquids, and ointments for health problems like heart disease, diabetes, and infections. It has five high-quality certified factories in Telangana and Andhra Pradesh, sells medicines in India and other countries like Australia, New Zealand, Southeast Asia, the Middle East, and Africa, and is growing by improving its factories and buying Noumed Pharmaceuticals.
What is Sai Parenterals Ltd?
Sai Parenterals is an Indian medicine company started in 2001 in Hyderabad, Telangana, and is owned by Mr Anil Kumar Karusala. The company makes different types of medicines, especially injectable ones like vials and syringes, as well as tablets and capsules. It also helps other medicine companies by making their products and conducting research. The company keeps high-quality standards with WHO-GMP and ISO-certified factories. It sells medicines in India and also exports to countries like Australia, the Middle East, and Africa, while growing its business through new factories, research, and buying other companies.
It is a well-known medicine company from India that makes different types of medicines and helps improve health around the world. The company makes its own branded medicines and also helps other companies make their medicines, which is called CDMO services. It focuses on making safe, high-quality products that follow strict rules. Its medicines cover many health needs and are made with modern technology and skilled scientific teams. In 2026, its share price target would be ₹900, as per stock market analysts.
According to stock market analysts, its share price would be between ₹310 to ₹900 in 2026.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 310 | 900 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | — | — |
| February | — | — |
| March | — | — |
| April | 351 | 479 |
| May | 310 | 574 |
| June | 387 | 636 |
| July | 474 | 678 |
| August | 523 | 700 |
| September | 589 | 745 |
| October | 636 | 789 |
| November | 714 | 852 |
| December | 810 | 900 |
The company offers affordable and safe healthcare through research and innovation. Its goal is to make good medicines available to people everywhere. It uses research and modern technology to create medicines that can treat many kinds of diseases. Through its work, the company tries to improve healthcare systems and help patients live healthier lives. In 2027, its share price target would be ₹1478, as per stock market analysts.
According to stock market analysts, its share price would be between ₹851 to ₹1478 in 2027.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2027 | 851 | 1478 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 851 | 990 |
| February | 887 | 1055 |
| March | 910 | 1087 |
| April | 942 | 1125 |
| May | 978 | 1174 |
| June | 990 | 1245 |
| July | 1044 | 1284 |
| August | 1075 | 1335 |
| September | 1121 | 1355 |
| October | 1174 | 1389 |
| November | 1224 | 1442 |
| December | 1287 | 1478 |
It makes medicines in many forms, including injections, tablets, capsules, liquids, and ointments. These medicines treat heart problems, breathing issues, infections, diabetes, skin problems, and more. The company is especially known for its sterile injections, such as vials, ampoules, and pre-filled syringes, which are made in very clean and safe conditions. Every product is carefully tested to make sure it is safe and effective. In 2028, its share price target would be ₹1933, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1415 to ₹1933 in 2028.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2028 | 1415 | 1933 |
The company has modern factories in India, mainly in Hyderabad, Telangana. These factories are certified with WHO-GMP and ISO standards, which means they meet international quality rules. It uses modern machines, clean rooms, and trained staff to make medicines for India and other countries. The factories have special areas for injections, oral medicines, and other types of products. In 2029, its share price target would be ₹2530, as per stock market analysts.
According to stock market analysts, its share price would be between ₹1882 to ₹2530 in 2029.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2029 | 1882 | 2530 |
It also helps other medicine companies through CDMO services. This means it supports them from research to the final product. These services include developing products, getting approvals, making the medicines, testing them, and packaging. Many companies choose this brand because it has skilled labs, strong quality systems, and experience in global markets. This helps smaller or new companies bring their medicines to people safely and quickly. In 2030, its share price target would be ₹3274, as per stock market analysts.
According to stock market analysts, its share price would be between ₹2478 to ₹3274 in 2030.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2030 | 2478 | 3274 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 2478 | 2611 |
| February | 2510 | 2674 |
| March | 2541 | 2725 |
| April | 2578 | 2774 |
| May | 2621 | 2835 |
| June | 2668 | 2887 |
| July | 2710 | 2936 |
| August | 2774 | 2988 |
| September | 2823 | 3047 |
| October | 2857 | 3078 |
| November | 2923 | 3155 |
| December | 2990 | 3274 |
Quality is very important for this company. The company follows international rules like WHO-GMP and ISO 9001 to make sure medicines are safe. These rules make sure the medicines are made in clean places, tested carefully, and meet strict safety standards. Regular checks by internal experts help keep quality high so doctors, hospitals, and patients can trust the medicines. In 2040, its share price target would be ₹6155, as per stock market analysts.
According to stock market analysts, its share price would be between ₹5448 to ₹6155 in 2040.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2040 | 5448 | 6155 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 5448 | 5623 |
| February | 5478 | 5677 |
| March | 5512 | 5745 |
| April | 5557 | 5789 |
| May | 5621 | 5842 |
| June | 5678 | 5895 |
| July | 5714 | 5936 |
| August | 5774 | 5978 |
| September | 5847 | 6012 |
| October | 5936 | 6055 |
| November | 5978 | 6078 |
| December | 5990 | 6155 |
It sells its medicines not only in India but also in many other countries. The company exports to Australia, New Zealand, Southeast Asia, the Middle East, and Africa. It helps meet healthcare needs worldwide. Its global presence shows that people and companies around the world trust its products, as it sells in different countries. In 2050, its share price target would be ₹10177, as per stock market analysts.
According to stock market analysts, its share price would be between ₹9358 to ₹10177 in 2050.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2050 | 9358 | 10177 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
| January | 9358 | 9541 |
| February | 9387 | 9589 |
| March | 9442 | 9625 |
| April | 9478 | 9678 |
| May | 9525 | 9725 |
| June | 9578 | 9774 |
| July | 9621 | 9821 |
| August | 9668 | 9884 |
| September | 9741 | 9936 |
| October | 9825 | 9990 |
| November | 9884 | 10078 |
| December | 9936 | 10177 |
Should I buy Sai Parenterals stock?
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
| 2026 | 310 | 900 |
| 2027 | 851 | 1478 |
| 2028 | 1415 | 1933 |
| 2029 | 1882 | 2530 |
| 2030 | 2478 | 3274 |
| 2040 | 5448 | 6155 |
| 2050 | 9358 | 10177 |
It is growing with its own branded medicines, helping other companies make medicines, and expanding to other countries. But it also faces risks like tough competition, rules, and market changes, but these challanges happens genrally with businesses. So, it could be a good choice for investors who can take some risk and think long-term, while cautious investors might wait for more stability before buying. The company has good products and experienced teams, which can help it grow in the future.
Sai Parenterals earnings results (Financials)
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| NET Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
| Amount in ₹ Crore | ||||
Is Sai Parenterals stock good to buy? (bull case & bear case)
Bull Case:
- This company reported revenue of ₹163.1 crore in FY25, up from ₹153.76 crore in FY24 and ₹96.79 crore in FY23, showing steady growth.
- It recorded PAT of ₹14.45 crore in FY25, compared with ₹8.41 crore in FY24 and ₹4.37 crore in FY23, showing rising profitability.
- Its EBITDA reached ₹40.0 crore in FY25, up from ₹33.06 crore in FY24 and ₹17.85 crore in FY23, reflecting stronger operating earnings.
- The company’s net worth increased to ₹95.77 crore in FY25 from ₹31.48 crore in FY23, indicating a healthier balance sheet.
- It operates five WHO-GMP certified facilities with an installed capacity of 1,160 million units per year, supporting exports and future growth.
Bear Case:
- Its revenue, though growing, is still modest at ₹163.1 crore in FY25 compared with larger pharma peers.
- PAT of ₹14.45 crore with ~8.84% margin shows that profits are moderate and could be vulnerable.
- The company relies on international exports and regulatory approvals, adding risk if rules or trade conditions change.
Conclusion
It makes many types of medicines like injections, tablets, capsules, liquids, and ointments, and also helps other companies make their products through CDMO services. The company has several WHO-GMP certified factories and sells its medicines in India and other countries like Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Even though it faces competition and regulatory risks, its experienced team, strong factories, and wide range of products make it a good choice for long-term investors who can take some risk.
